Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Share-based Compensation (2016 - 2025)

Rocket Pharmaceuticals' Share-based Compensation history spans 10 years, with the latest figure at $6.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 44.88% year-over-year to $6.1 million; the TTM value through Dec 2025 reached $37.1 million, down 15.62%, while the annual FY2025 figure was $37.1 million, 15.62% down from the prior year.
  • Share-based Compensation for Q4 2025 was $6.1 million at Rocket Pharmaceuticals, down from $9.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.3 million in Q2 2024 and bottomed at $6.1 million in Q4 2025.
  • The 5-year median for Share-based Compensation is $9.7 million (2022), against an average of $9.0 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 99.44% in 2021 before it crashed 44.88% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $7.0 million in 2021, then surged by 37.74% to $9.7 million in 2022, then grew by 2.45% to $9.9 million in 2023, then grew by 11.66% to $11.1 million in 2024, then crashed by 44.88% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Share-based Compensation are $6.1 million (Q4 2025), $9.8 million (Q3 2025), and $10.9 million (Q2 2025).